Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a weight-loss drug trial.

Scholar Rock said on Wednesday a combination of its experimental drug and Eli Lilly's weight-loss treatment Zepbound helped overweight patients preserve significantly more lean mass in a mid-stage ...

The Trump administration is weighing measures that would make it more expensive for pharmaceutical companies to conduct ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body ...

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

The Department of Health and Human Services is allegedly denying clinical trial funding for biotechs based on their ties to ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly's Zepbound is the first and only approved dual GLP-1/GIP agonist, and Lilly is also working on its own triple ...

Streaming Finally Outpaces Traditional TV. The Leading Platform Might Surprise You. YouTube represented 12.5% of all television viewing in May-the highest share of TV for any streamer to date. The new ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.